Where Antimicrobial Peptides Come From

Antimicrobial Peptides

3,000+ Known AMPs

The Antimicrobial Peptide Database catalogs over 3,000 natural antimicrobial peptides from across all kingdoms of life, with hundreds more discovered each year.

APD3 Database, Wang et al.

APD3 Database, Wang et al.

View as image

Every multicellular organism on Earth makes antimicrobial peptides. Frogs secrete them from their skin. Insects produce them in their fat bodies. Horseshoe crabs pack them into blood cells. Even deep-sea sponges and bacteria manufacture peptides that kill competing microbes. These molecules are the oldest immune defense system in biology, predating adaptive immunity by hundreds of millions of years. As antibiotic resistance escalates, researchers are turning to these natural peptide arsenals for the next generation of anti-infective drugs. This article maps the major source organisms, the peptides they produce, and why marine AMPs in particular are attracting intense research interest.

Amphibians: The Richest Vertebrate Source

The modern era of antimicrobial peptide research began with a frog. In 1987, Michael Zasloff was studying gene expression in the African clawed frog (Xenopus laevis) at the National Institutes of Health. He noticed something peculiar: after surgical procedures, the frogs healed rapidly in bacteria-laden tank water without developing infections. Investigation revealed that their skin secreted a class of previously unknown peptides with broad-spectrum antimicrobial activity.^[1]

Zasloff named them magainins, from the Hebrew word for shield. The two primary magainins (magainin 1 and magainin 2) are each 23 amino acids long. At micromolar concentrations, they kill numerous bacterial species, fungi, and protozoa. Their mechanism: the positively charged, amphipathic peptides insert into negatively charged bacterial membranes, forming pores that cause the cell to burst. Crucially, they show minimal toxicity against mammalian cells, whose membranes have a different charge distribution.

Zasloff's discovery opened the floodgates. Since 1987, researchers have identified over 1,000 AMPs from amphibian skin, spanning more than 200 frog species. The peptides fall into several structural families:

• Magainins (Xenopus laevis): the founding family, alpha-helical peptides with broad-spectrum activity
• Dermaseptins (Phyllomedusa tree frogs): 24-34 amino acid peptides active against bacteria, fungi, and parasites including Plasmodium (the malaria parasite)
• Bombinins (Bombina fire-bellied toads): among the earliest discovered AMPs, first isolated in 1962
• Temporins (Rana temporaria): unusually short AMPs (10-14 amino acids), among the smallest known natural antimicrobials
• Brevinins and esculentins (Rana and Pelophylax frogs): potent against gram-negative bacteria

Why are frogs such prolific AMP producers? Their skin is a permeable interface between the internal body and a pathogen-rich aquatic environment. Unlike mammals, frogs lack keratin barriers, scales, or shells. Their skin must simultaneously manage gas exchange, water balance, and pathogen defense. AMPs are the solution: a chemical shield that kills microbes on contact without blocking the skin's other functions.

For a deeper exploration of frog skin peptides and how amphibians defend against infection, see the linked article.

Insects: The Most Diverse AMP Arsenal

Insects are the largest and most diverse animal group on Earth, and their AMPs reflect that diversity. With no adaptive immune system (no antibodies, no T-cells), insects rely entirely on innate immunity, and peptides are its primary weapon.

The discovery timeline parallels amphibians. In 1980, Hans Boman and colleagues identified cecropins from the hemolymph (insect blood) of the giant silk moth Hyalophora cecropia. This was the first antimicrobial peptide isolated from an insect and one of the earliest AMPs characterized from any animal.

Cecropins are 35-39 amino acid alpha-helical peptides that kill gram-negative bacteria by membrane disruption. They are non-toxic to mammalian cells. Dozens of cecropin variants have been identified across Lepidoptera (moths and butterflies), Diptera (flies), and other insect orders. A 2019 review by Brady et al. documented the therapeutic potential of insect cecropins, noting their activity against multidrug-resistant bacteria and their amenability to synthetic modification.

Other major insect AMP families:

• Insect defensins: structurally distinct from mammalian defensins, these cysteine-stabilized peptides are active primarily against gram-positive bacteria. Found in virtually all insect orders studied
• Attacins: large (20 kDa) proteins that inhibit outer membrane protein synthesis in gram-negative bacteria. Originally isolated from Hyalophora cecropia alongside cecropins
• Drosocin and pyrrhocoricin: proline-rich peptides from Drosophila and other insects that penetrate bacterial cells and inhibit the chaperone protein DnaK, blocking protein folding
• Melittin: a 26-amino acid peptide from honeybee venom, technically a cytolytic toxin but with potent antimicrobial properties. Its high toxicity to mammalian cells limits direct use, but hybrid peptides combining melittin fragments with cecropin sequences show improved selectivity

Insects offer practical advantages as AMP sources. They are small, inexpensive to rear, and breed rapidly. Their peptides are encoded by well-characterized genes that can be expressed recombinantly in bacterial or yeast systems, enabling large-scale production. The stick insect genome alone contains over 20 AMP genes, and new insect AMPs are being identified through genomic screening at accelerating rates.

For detailed coverage of insect cecropins and their therapeutic applications, see the linked article.

Marine Organisms: Salt-Stable Peptides for a Saline World

Marine AMPs solve a problem that plagues their terrestrial counterparts: salt sensitivity. Many AMPs from frogs and insects lose activity in physiological salt concentrations (150 mM NaCl). This is a barrier to clinical use, since human blood and tissue are saline environments. Marine organisms, living in seawater at roughly 500 mM NaCl, produce peptides that maintain activity in high-salt conditions by default.

Horseshoe crabs

The horseshoe crab (Limulus polyphemus and related species) is among the oldest living animal lineages, largely unchanged for 450 million years. Its immune system is entirely innate and remarkably effective. Horseshoe crab blood cells (amebocytes) contain several AMPs:

• Tachyplesin: an 18-amino acid beta-hairpin peptide stabilized by two disulfide bonds. Active against gram-negative and gram-positive bacteria, fungi, and enveloped viruses including HIV and influenza. Its rigid structure maintains activity in high-salt conditions
• Polyphemusin: closely related to tachyplesin, isolated from Limulus polyphemus, with similar broad-spectrum activity
• Big defensin: a larger antimicrobial protein found in multiple horseshoe crab species

Horseshoe crab blood has long been used in the Limulus amebocyte lysate (LAL) test, the global standard for detecting bacterial endotoxin in pharmaceutical products. The AMPs in their blood are part of the same defense system.

Marine invertebrates

Sponges, tunicates, sea anemones, and mollusks produce AMPs with unique structural features:

• Clavanins (tunicates): alpha-helical, histidine-rich peptides that maintain activity at low pH and in salt-rich environments
• Arenicin (polychaete worms): beta-hairpin peptides with potent anti-gram-negative activity
• Myticins and mytilins (mussels): cysteine-stabilized peptides that protect filter-feeding bivalves from the constant microbial exposure in their aquatic environment

Marine bacteria and fungi

Marine microbes produce AMPs (often called bacteriocins in the bacterial context) as weapons against competing organisms. Deep-sea and hydrothermal vent bacteria, living under extreme pressure and temperature, produce peptides with unusual stability that are of particular interest for drug development.

For comprehensive coverage of marine antimicrobial peptides as a therapeutic resource, see the pillar article.

Mammals: Your Own AMP Arsenal

Humans and other mammals produce two major families of AMPs:

Cathelicidins: LL-37 is the only human cathelicidin. It is a 37-amino acid peptide released from neutrophils, macrophages, and epithelial cells at sites of infection. LL-37 kills bacteria through membrane disruption, neutralizes endotoxin, and modulates the immune response. Its roles in gut defense, respiratory immunity, and microbiome regulation are covered in dedicated articles.

Defensins: alpha-defensins are stored in neutrophil granules and released during bacterial killing. Beta-defensins are produced by epithelial cells in the skin, lungs, gut, and urogenital tract. Theta-defensins are circular peptides found in some primates (not humans, though the gene is present as a pseudogene).

Mammalian AMPs serve as both direct killers and immune modulators. They recruit immune cells to infection sites, promote wound healing, and can even influence adaptive immune responses. This dual functionality makes them fundamentally different from conventional antibiotics, which only kill.

Plants: The Overlooked Kingdom

Plants cannot flee from pathogens. Their AMP production reflects this constraint. Plant defensins, thionins, and lipid transfer proteins provide constitutive and inducible defense against bacterial, fungal, and viral pathogens.

• Plant defensins: small (45-54 amino acid), cysteine-rich peptides found in seeds, leaves, and roots. Some plant defensins have potent antifungal activity (e.g., NaD1 from Nicotiana alata flowers)
• Cyclotides: cyclic peptides with a knotted disulfide structure, found in the Violaceae (violet) and Rubiaceae (coffee) families. Their circular backbone makes them extraordinarily resistant to enzymatic degradation, which is rare among peptides
• Hevein-like peptides: chitin-binding peptides that interfere with fungal cell wall synthesis

Cyclotides are particularly interesting for drug development because their cyclic structure gives them stability that linear peptides lack. They survive gastric digestion, raising the possibility of oral antimicrobial peptide drugs, a goal that has proven difficult with linear AMPs.

Bacteria: Fighting Fire with Fire

Bacteria themselves produce antimicrobial peptides, typically called bacteriocins, as weapons against competing bacterial species. The most commercially successful AMP in history is a bacteriocin: nisin, produced by Lactococcus lactis, has been used as a food preservative for over 50 years and is approved as a food additive in more than 80 countries.

Bacteriocins are classified by structure:

• Lantibiotics (including nisin): contain unusual amino acids formed by post-translational modification, giving them enhanced stability
• Microcins: small peptides produced by Enterobacteriaceae, often with novel mechanisms of action
• Class II bacteriocins: unmodified peptides that kill through membrane permeabilization

The advantage of bacteriocins as drug candidates: they have already evolved to function in the chemical environment of the human body (the gut, the skin), since many bacteriocin-producing organisms are human commensals. Understanding how gut bacteria produce antimicrobial peptides reveals how the microbiome maintains its own internal balance through peptide warfare.

From Nature to Pharmacy: Why Source Matters

Natural AMPs are starting points, not finished drugs. Raw frog skin peptides are too hemolytic (they burst red blood cells). Insect peptides may be too immunogenic. Marine peptides may have off-target toxicity.

But natural diversity provides the structural templates that synthetic AMP design builds on. Researchers modify natural peptides to improve selectivity (killing bacteria while sparing human cells), stability (resisting enzymatic breakdown in blood), and potency (lowering the concentration needed). The Antimicrobial Peptide Database (APD3) catalogs over 3,000 natural AMPs, serving as a library of structural motifs that computational design tools can recombine and optimize.

The antibiotic resistance crisis makes this work urgent. AMPs kill through physical membrane disruption, a mechanism that is harder for bacteria to evolve resistance against than the specific enzyme targets of conventional antibiotics. Bacteria can mutate a single enzyme to evade penicillin. Redesigning an entire membrane to evade AMPs is orders of magnitude more difficult.

The Bottom Line

Antimicrobial peptides exist across all kingdoms of life, from frog skin to insect blood to deep-sea sponges. Amphibians are the richest vertebrate source, with over 1,000 identified AMPs. Insects offer the most diversity and scalability. Marine organisms produce uniquely salt-stable peptides critical for clinical translation. Each source contributes structural templates that synthetic design can optimize into drugs, addressing the antibiotic resistance crisis through a mechanism (membrane disruption) that is inherently harder for bacteria to resist.

Frequently Asked Questions

What animals produce antimicrobial peptides?

Virtually all multicellular animals produce antimicrobial peptides as part of their innate immune system. The richest sources are amphibians (over 1,000 AMPs from frog skin alone), insects (cecropins, defensins, attacins), and marine invertebrates (horseshoe crabs, mussels, sponges). Mammals, including humans, produce cathelicidins and defensins. Even simple organisms like Hydra and sea anemones produce AMPs.

What was the first antimicrobial peptide discovered?

One of the earliest animal AMPs was bombinin, discovered from the skin of the fire-bellied toad (Bombina) in 1962. However, the discovery that launched modern AMP research was Zasloff's 1987 isolation of magainins from the African clawed frog Xenopus laevis. The first insect AMP, cecropin, was isolated from the giant silk moth by Boman and colleagues in 1980.

Why are frog peptides antimicrobial?

Frog skin is a permeable membrane exposed to water teeming with bacteria and fungi. Unlike reptiles or mammals, frogs lack protective scales or keratin barriers. They compensate with chemical defense: glands in the skin secrete AMPs that kill pathogens on contact through membrane disruption. Zasloff's magainins, for example, form pores in bacterial membranes at micromolar concentrations while leaving frog cells unharmed.

What are marine antimicrobial peptides?

Marine antimicrobial peptides are defense molecules produced by ocean-dwelling organisms including horseshoe crabs (tachyplesin), mussels (myticins), tunicates (clavanins), and sea sponges. Their key advantage over terrestrial AMPs: they maintain antimicrobial activity in high-salt environments (seawater is ~500 mM NaCl), which is critical because many frog and insect AMPs lose potency at the salt concentrations found in human blood and tissue.

Can antimicrobial peptides replace antibiotics?

AMPs are being developed as complements to, not replacements for, conventional antibiotics. Their membrane-disrupting mechanism makes resistance harder to evolve, addressing a key limitation of existing drugs. Several AMPs are in clinical trials for wound infections, topical antimicrobials, and catheter coatings. Oral and systemic AMP drugs remain challenging due to stability and manufacturing costs, though cyclic peptides like cyclotides show promise for oral delivery.

How do antimicrobial peptides kill bacteria?

Most AMPs kill bacteria through physical disruption of the cell membrane. The positively charged peptide binds to the negatively charged bacterial membrane surface, inserts into the lipid bilayer, and forms pores or carpets that cause the cell contents to leak out. This is fundamentally different from antibiotics, which typically inhibit a single enzyme. Some AMPs (like proline-rich peptides from insects) enter the cell and inhibit internal targets like protein folding.